Fenwick-Backed Life Sciences Co. Files For $125M IPO
A Fenwick-represented life sciences company developing gene therapies for diseases of the central nervous system hopes to raise up to $125 million in an initial public offering, according to documents filed...To view the full article, register now.
Already a subscriber? Click here to view full article